Global access to diagnostics is constrained not only by the availability of testing technologies but also by their dependence on costly supply chains that typically originate from a small number of capital-intensive biotechnology hubs. Here, we argue that integrating decentralized diagnostics with local manufacturing and research capacity is essential to building resilient, equitable and sustainable diagnostic ecosystems.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: